Unknown

Dataset Information

0

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.


ABSTRACT:

Background

African American breast cancer patients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtype within clinically defined subgroups are not well understood.

Methods

Using data and biospecimens from the population-based Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified 980 invasive breast cancers using RNA expression-based PAM50 subtype and recurrence (ROR) score that reflects proliferation and tumor size. Molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Basal-like) and ROR scores (high vs low/medium) were compared by race (blacks vs whites) and age (?50?years vs?>?50?years) using chi-square tests and analysis of variance tests.

Results

Black women of all ages had a statistically significantly lower frequency of Luminal A breast cancer (25.4% and 33.6% in blacks vs 42.8% and 52.1% in whites; younger and older, respectively). All other subtype frequencies were higher in black women (case-only odds ratio [OR] = 3.11, 95% confidence interval [CI] = 2.22 to 4.37, for Basal-like; OR?=?1.45, 95% CI?=?1.02 to 2.06, for Luminal B; OR?=?2.04, 95% CI?=?1.33 to 3.13, for HER2-enriched). Among clinically HR+/HER2- cases, Luminal A subtype was less common and ROR scores were statistically significantly higher among black women.

Conclusions

Multigene assays highlight racial disparities in tumor subtype distribution that persist even in clinically defined subgroups. Differences in tumor biology (eg, HER2-enriched status) may be targetable to reduce disparities among clinically ER+/HER2- cases.

SUBMITTER: Troester MA 

PROVIDER: S-EPMC6059138 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>African American breast cancer patients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtype within clinically defined subgroups are not well understood.<h4>Methods</h4>Using data and biospecimens from the population-based Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified 980 invasive breast cancers using RNA ex  ...[more]

Similar Datasets

| S-EPMC6825567 | biostudies-literature
| S-EPMC4452445 | biostudies-literature
2020-07-16 | GSE148426 | GEO
| S-EPMC3029098 | biostudies-literature
2020-07-16 | GSE148425 | GEO
| S-EPMC7259379 | biostudies-literature
| S-EPMC10771357 | biostudies-literature
2015-04-07 | GSE51557 | GEO
2020-07-16 | GSE148418 | GEO
2015-04-07 | E-GEOD-51557 | biostudies-arrayexpress